A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial

Kathy J Baisley, Hilary S Whitworth, John Changalucha, Ligia Pinto, Joakim Dillner, Saidi Kapiga, Silvia de Sanjosé, Philippe Mayaud, Richard J Hayes, Charles J Lacey, Deborah Watson-Jones, Kathy J Baisley, Hilary S Whitworth, John Changalucha, Ligia Pinto, Joakim Dillner, Saidi Kapiga, Silvia de Sanjosé, Philippe Mayaud, Richard J Hayes, Charles J Lacey, Deborah Watson-Jones

Abstract

Background: Human papillomavirus (HPV) infection is the primary cause of cervical cancer. In 2018, the World Health Organization (WHO) Director General announced his commitment to eliminate cervical cancer, with HPV vaccination as a priority. However, the costs of setting up a multi-dose HPV vaccination programme remain a barrier to its introduction.

Methods/design: We are conducting a randomised-controlled trial of reduced dose schedules of HPV vaccine in Tanzania to establish whether a single dose produces immune responses that will be effective in preventing cervical cancer. 930 girls aged 9-14 years in Mwanza, Tanzania, were randomised to one of 6 arms, comprising 3 different dose schedules of the 2-valent (Cervarix) and 9-valent (Gardasil-9) HPV vaccines: 3 doses; 2 doses given 6 months apart; or a single dose. All participants will be followed for 36 months; those in the 1 and 2 dose arms will be followed for 60 months. Trial outcomes focus on vaccine immune responses including HPV 16/18-specific antibody levels, antibody avidity, and memory B cell responses. Results will be immunobridged to historical cohorts of girls and young women in whom efficacy has been demonstrated.

Discussion: This is the first randomised trial of the single dose HPV vaccine schedule in the target age group. The trial will allow us to examine the quality and durability of immune responses of reduced dose schedules in a population with high burden of malaria and other infections that may affect vaccine immune responses. Initial results (24 months) are expected to be published in early 2021.

Keywords: Growth performance; Microbiota; Olive flounder; Probiotic.

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424.
    1. World Health Organization Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 -- conclusions and recommendations. Wkly Epidemiol. Rec. 2014;89(21):221–236.
    1. Quentin W., Terris-Prestholt F., Changalucha J., Soteli S., Edmunds W.J., Hutubessy R. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med. 2012;10:137.
    1. Levin C.E., Van Minh H., Odaga J., Rout S.S., Ngoc D.N., Menezes L. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bull. World Health Organ. 2013;91(8):585–592.
    1. Bosch F.X., Robles C., Díaz M., Arbyn M., Baussano I., Clavel C. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat. Rev. Clin. Oncol. 2016;13(2):119–132.
    1. Kreimer A.R., Struyf F., Del Rosario-Raymundo M.R., Hildesheim A., Skinner S.R., Wacholder S. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. The Lancet Oncology. 2015;16(7):775–786.
    1. Kreimer A.R., Sampson J.N., Porras C., Schiller J.T., Kemp T., Herrero R. Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial. J Natl Cancer Inst. 2020 Feb 24;112(10):1038–1046. djaa011.
    1. Sankaranarayanan R., Joshi S., Muwonge R., Esmy P.O., Basu P., Prabhu P. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36(32 Pt A):4783–4791.
    1. Lehtinen M., Herrero R., Mayaud P., Barnabas R., Dillner J., Paavonen J. Chapter 28: studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine. 2006;24(Suppl. 3):S3/233–S3/241.
    1. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374–1386.
    1. Watson-Jones D., Baisley K., Brown J., Kavishe B., Andreasen A., Changalucha J. High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. Sex. Transm. Infect. 2013;89:358–365.
    1. Houlihan C.F., Baisley K., Bravo I.G., Kapiga S., de Sanjosé S., Changalucha J. The incidence of human papillomavirus in Tanzanian adolescent girls before reported sexual debut. J. Adolesc. Health. 2016 Mar;58(3):295–301.
    1. Baisley K.J., Andreasen A., Irani J., Nnko S., Changalucha J., Crucitti T. HPV prevalence around the time of sexual debut in adolescent girls in Tanzania. Sex. Transm. Infect. 2020 May;96(3):211–219.
    1. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–1802.
    1. Harper D.M., DeMars L.R. HPV vaccines - a review of the first decade. Gynecol. Oncol. 2017 Jul;146(1):196–204.
    1. Einstein M.H., Takacs P., Chatterjee A., Sperling R.S., Chakhtoura N., Blatter M.M. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother. 2014;10(12):3435–3445.
    1. Kemp T.J., Garcia-Pineres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine. 2008;26(29–30):3608–3616.
    1. Dauner J.G., Pan Y., Hildesheim A., Kemp T.J., Porras C., Pinto L.A. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol. Cell. Probes. 2012;26(2):73–78.
    1. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011;7(12):1343–1358.
    1. Faust H., Jelen M.M., Poljak M., Klavs I., Ucakar V., Dillner J. Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. J. Clin. Virol. 2013;56(4):336–341.
    1. Faust H., Toft L., Sehr P., Muller M., Bonde J., Forslund O. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559–1565.
    1. Artemchuk H., Triglav T., Oštrbenk A., Poljak M., Dillner J., Faust H. Seroprevalences of antibodies to 11 human papillomavirus (HPV) types mark cumulative HPV exposure. J. Infect. Dis. 2018;218(3):398–405.
    1. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295(10):1152–1160.
    1. Farrington C.P., Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or nonunity relative risk. Stat. Med. 1990;9:1447–1454.
    1. Liu M., Li Q., Lin J., Lin Y., Hoffman E. Innovative trial designs and analyses for vaccine clinical development. Contemp Clin Trials. 2020 Nov 21;100:106225.
    1. Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Gonzalez P., Kreimer A.R. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1:408–419.
    1. World Health Organisation . IARC Working Group Report; France: 2014. World Health Organisation Primary End-points for Prophylactic HPV Vaccine Trials.
    1. Brown J., Baisley K., Kavishe B., Changalucha J., Andreasen A., Mayaud P. Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania. Vaccine. 2014;32(5):611–617.
    1. Perlmann P., Troye-Blomberg M. Malaria and the immune system in humans. Chem. Immunol. 2002;80:229–242.
    1. World Health Organization Meeting of the Strategic Advisory Group of Experts on Immunization, October 2018 – conclusions and recommendations, Dec 2018. Wkly Epidemiol. Rec. 2018;49(93):661–680.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren